Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
IONS filing amends a Form 144 reporting proposed sales of Common Stock by a selling holder. The filing lists sales dated 01/16/2026 and 01/30/2026 with reported quantities of 9,302 and 6,179 respectively. The securities are listed as Common Stock on Nasdaq.
Ionis Pharmaceuticals executive Eugene Schneider reported an open-market sale of 5,812 shares of Common Stock. The shares were sold at a weighted average price of $70.9715 per share on March 19, 2026, under a pre-arranged Rule 10b5-1 trading plan. After the transaction, Schneider directly holds 63,890 shares.
IONS affiliate filed a Form 144 to sell Common Stock. The notice lists proposed sales tied to 01/15/2026 performance stock units and a reported sale on 03/19/2026. The filing names Stifel Nicolaus & Company as broker and lists quantities including 6179 shares sold in the past three months and figure 512906.00.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported a series of stock option exercises followed by open-market sales of common stock. On March 16, 2026, she exercised options to acquire a total of 174,999 shares of common stock at exercise prices of $32.6000, $37.5800, $56.7800 and $60.8900 per share. That same day, she sold 215,048 shares of common stock in open-market transactions at weighted average prices of $72.3810 and $72.7650 per share. On March 17, 2026, she sold an additional 10,172 shares at a weighted average price of $73.2070 per share, bringing total reported sales to 225,220 shares. The filing states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Following the transactions, Hougen directly owns 82,660 shares of Ionis common stock.
IONS notice of proposed resale of 225,200 shares of Common Stock. The form lists 225,200 shares to be sold pursuant to an option exercise with cash proceeds and identifies Stifel Nicolaus & Company Inc as a broker. The filing also records two prior dispositions by Elizabeth Hougen of 6,988 and 12,922 shares on 01/30/2026 and 01/16/2026, respectively, with their cash amounts.
Ionis Pharmaceuticals executive Patrick R. O'Neil reported an open-market sale of 10,148 shares of common stock at an average price of $75.2525 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Following this sale, O'Neil directly holds 62,211 Ionis shares. The reported sale price reflects a weighted average, with individual trades completed between $74.98 and $75.51 per share.
Ionis Pharmaceuticals Chief Executive Officer Brett P. Monia reported a series of option exercises and stock sales. On March 9–10, 2026, Monia exercised non-qualified stock options covering 148,454 shares of common stock at an exercise price of $60.89 per share.
Across the same two days, Monia sold 160,773 shares of common stock in open-market transactions at weighted average prices in the mid‑$70 range. These sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transactions, Monia directly owns 242,662 shares of Ionis Pharmaceuticals common stock.
Ionis Pharmaceuticals EVP Kyle Jenne exercised stock options and sold shares in a planned trade. He exercised options for 37,277 shares of Common Stock at exercise prices of $34.69 and $46.10 per share, then sold 37,277 shares in open-market transactions at weighted average prices of $75.502 and $76.30 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, Jenne directly holds 16,389 shares of Ionis Pharmaceuticals Common Stock.
IONS filed a Form 144 notifying proposed sales of Common Stock. The notice lists two option-exercise related lots of 4,675 and 32,602 shares scheduled on 03/10/2026 to be sold for cash. The filing also reports a prior sale of 1,823 shares on 01/16/2026 for $138,963 by Kyle Jenne.
IONS filing reports proposed sales of Common Stock by Patrick O'Neil. The document lists two transactions: 9,191 shares on 01/06/2026 for $700,602.00 and 6,179 shares on 01/30/2026 for $512,905.00. The filing also references Restricted Stock Units dated 01/15/2018 and an indicated share count of 165,190,000 as of 03/09/2026.